These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20179679)

  • 1. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.
    Heldermon CD; Ohlemiller KK; Herzog ED; Vogler C; Qin E; Wozniak DF; Tan Y; Orrock JL; Sands MS
    Mol Ther; 2010 May; 18(5):873-80. PubMed ID: 20179679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.
    Heldermon CD; Qin EY; Ohlemiller KK; Herzog ED; Brown JR; Vogler C; Hou W; Orrock JL; Crawford BE; Sands MS
    Gene Ther; 2013 Sep; 20(9):913-21. PubMed ID: 23535899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis.
    Macauley SL; Roberts MS; Wong AM; McSloy F; Reddy AS; Cooper JD; Sands MS
    Ann Neurol; 2012 Jun; 71(6):797-804. PubMed ID: 22368049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice.
    Fu H; Kang L; Jennings JS; Moy SS; Perez A; Dirosario J; McCarty DM; Muenzer J
    Gene Ther; 2007 Jul; 14(14):1065-77. PubMed ID: 17460717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
    Holley RJ; Ellison SM; Fil D; O'Leary C; McDermott J; Senthivel N; Langford-Smith AWW; Wilkinson FL; D'Souza Z; Parker H; Liao A; Rowlston S; Gleitz HFE; Kan SH; Dickson PI; Bigger BW
    Brain; 2018 Jan; 141(1):99-116. PubMed ID: 29186350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
    Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
    J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10.
    Gilkes JA; Bloom MD; Heldermon CD
    Gene Ther; 2016 Mar; 23(3):263-71. PubMed ID: 26674264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe Disease.
    Li Y; Miller CA; Shea LK; Jiang X; Guzman MA; Chandler RJ; Ramakrishnan SM; Smith SN; Venditti CP; Vogler CA; Ory DS; Ley TJ; Sands MS
    Mol Ther; 2021 Feb; 29(2):691-701. PubMed ID: 33388420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery.
    Fu H; Samulski RJ; McCown TJ; Picornell YJ; Fletcher D; Muenzer J
    Mol Ther; 2002 Jan; 5(1):42-9. PubMed ID: 11786044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.
    Roca C; Motas S; Marcó S; Ribera A; Sánchez V; Sánchez X; Bertolin J; León X; Pérez J; Garcia M; Villacampa P; Ruberte J; Pujol A; Haurigot V; Bosch F
    Hum Mol Genet; 2017 Apr; 26(8):1535-1551. PubMed ID: 28334745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy.
    Reddy AS; Kim JH; Hawkins-Salsbury JA; Macauley SL; Tracy ET; Vogler CA; Han X; Song SK; Wozniak DF; Fowler SC; Klein RS; Sands MS
    J Neurosci; 2011 Jul; 31(27):9945-57. PubMed ID: 21734286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome.
    Gougeon ML; Poirier-Beaudouin B; Ausseil J; Zérah M; Artaud C; Heard JM; Deiva K; Tardieu M
    Front Immunol; 2021; 12():655478. PubMed ID: 34040605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.
    Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM
    J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.
    Fu H; Meadows AS; Ware T; Mohney RP; McCarty DM
    Mol Ther; 2017 Mar; 25(3):792-802. PubMed ID: 28143737
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Marcó S; Haurigot V; Bosch F
    Hum Gene Ther; 2019 Oct; 30(10):1211-1221. PubMed ID: 31482754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.
    Fu H; Dirosario J; Killedar S; Zaraspe K; McCarty DM
    Mol Ther; 2011 Jun; 19(6):1025-33. PubMed ID: 21386820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
    Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
    Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.
    Ribera A; Haurigot V; Garcia M; Marcó S; Motas S; Villacampa P; Maggioni L; León X; Molas M; Sánchez V; Muñoz S; Leborgne C; Moll X; Pumarola M; Mingozzi F; Ruberte J; Añor S; Bosch F
    Hum Mol Genet; 2015 Apr; 24(7):2078-95. PubMed ID: 25524704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy.
    Lin D; Donsante A; Macauley S; Levy B; Vogler C; Sands MS
    Mol Ther; 2007 Jan; 15(1):44-52. PubMed ID: 17164774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.